FY2025 Earnings Forecast for AMLX Issued By Leerink Partnrs

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) – Leerink Partnrs raised their FY2025 earnings per share (EPS) estimates for Amylyx Pharmaceuticals in a report issued on Wednesday, January 29th. Leerink Partnrs analyst M. Goodman now expects that the company will post earnings of ($1.35) per share for the year, up from their previous estimate of ($1.75). The consensus estimate for Amylyx Pharmaceuticals’ current full-year earnings is ($2.84) per share. Leerink Partnrs also issued estimates for Amylyx Pharmaceuticals’ FY2026 earnings at ($1.35) EPS, FY2027 earnings at ($1.05) EPS and FY2028 earnings at ($1.00) EPS.

A number of other research firms also recently weighed in on AMLX. Leerink Partners set a $4.00 price target on shares of Amylyx Pharmaceuticals and gave the stock a “market perform” rating in a research report on Friday, October 18th. Bank of America raised shares of Amylyx Pharmaceuticals from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $4.20 to $10.00 in a report on Wednesday, October 23rd. HC Wainwright restated a “buy” rating and issued a $12.00 target price on shares of Amylyx Pharmaceuticals in a research note on Thursday, December 5th. Robert W. Baird upgraded Amylyx Pharmaceuticals from a “neutral” rating to an “outperform” rating and lifted their price target for the stock from $3.00 to $11.00 in a research note on Monday, November 18th. Finally, Baird R W raised Amylyx Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Monday, November 18th. Five investment analysts have rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $7.33.

Amylyx Pharmaceuticals Stock Performance

Shares of NASDAQ AMLX opened at $3.51 on Friday. The business has a 50 day moving average price of $4.21 and a two-hundred day moving average price of $3.61. Amylyx Pharmaceuticals has a fifty-two week low of $1.58 and a fifty-two week high of $19.95.

Insider Activity at Amylyx Pharmaceuticals

In related news, CEO Justin B. Klee sold 7,471 shares of the business’s stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $4.04, for a total transaction of $30,182.84. Following the completion of the transaction, the chief executive officer now owns 3,176,788 shares in the company, valued at $12,834,223.52. The trade was a 0.23 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 11.70% of the company’s stock.

Institutional Investors Weigh In On Amylyx Pharmaceuticals

Large investors have recently added to or reduced their stakes in the stock. Blue Trust Inc. grew its position in shares of Amylyx Pharmaceuticals by 232.1% during the fourth quarter. Blue Trust Inc. now owns 6,987 shares of the company’s stock worth $26,000 after acquiring an additional 4,883 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its stake in Amylyx Pharmaceuticals by 63.9% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,094 shares of the company’s stock valued at $42,000 after purchasing an additional 5,104 shares during the period. Algert Global LLC bought a new position in Amylyx Pharmaceuticals in the 2nd quarter worth about $47,000. Hsbc Holdings PLC increased its stake in shares of Amylyx Pharmaceuticals by 57.9% in the second quarter. Hsbc Holdings PLC now owns 76,261 shares of the company’s stock valued at $150,000 after purchasing an additional 27,954 shares during the period. Finally, Barclays PLC raised its holdings in shares of Amylyx Pharmaceuticals by 91.1% during the third quarter. Barclays PLC now owns 84,572 shares of the company’s stock valued at $274,000 after buying an additional 40,319 shares during the last quarter. 95.84% of the stock is owned by institutional investors and hedge funds.

Amylyx Pharmaceuticals Company Profile

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.